The U.S. Food and Drug Administration has approved Merck’s Idvynso (doravirine/islatravir), a new, once-daily, two-drug single tablet for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL).

Establishing it as the first ever reusable intermittent urinary catheter system and creating a new device classification in an industry that exclusively relied on single-use catheters for decades

Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.

The TAVVE study will begin later this year with ten patients, whose 30-day safety results will be submitted to the FDA.